Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.

TitleRadiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance.
Publication TypeJournal Article
Year of Publication2011
AuthorsSchoellnast H, Larson SM, Nehmeh SA, Carrasquillo JA, Thornton RH, Solomon SB
JournalCardiovasc Intervent Radiol
Volume34 Suppl 2
PaginationS182-5
Date Published2011 Feb
ISSN1432-086X
KeywordsAged, Biopsy, Carcinoma, Non-Small-Cell Lung, Catheter Ablation, Fluorodeoxyglucose F18, Humans, Image Processing, Computer-Assisted, Lung, Lung Neoplasms, Male, Neoplasm Recurrence, Local, Neoplasm Staging, Neoplasms, Multiple Primary, Pneumonectomy, Positron-Emission Tomography, Postoperative Complications, Reoperation, Surgery, Computer-Assisted, Tomography, X-Ray Computed
Abstract

Radiofrequency ablation (RFA) is a well-established method in treatment of patients with lung carcinomas who are not candidates for surgical resection. Usually computed tomographic (CT) guidance is used for the procedure, thus enabling needle placement and permitting evaluation of complications such as pneumothorax and bleeding. (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is generally used for tumor activity assessment and is therefore useful in follow-up after tumor treatment. A method that provides real-time image-based monitoring of RFA to ensure complete tumor ablation would be a valuable tool. In this report, we describe the behavior of preinjected FDG during PET CT-guided RFA of a non-small-cell lung carcinoma and discuss the value of FDG as a tool to provide intraprocedure monitor ablation. The size and the form of the activity changed during ablation. Ablation led to increase of the size and blurring and irregularity of the contour compared to pretreatment imaging. The maximal standardized uptake value decreased only slightly during the procedure. Therefore, before RFA, FDG PET can guide initial needle placement, but it does not serve as a monitoring tool to evaluate residual viable tissue during the procedure.

DOI10.1007/s00270-010-9898-7
Alternate JournalCardiovasc Intervent Radiol
PubMed ID20508937

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065